CLINICAL TRIALS OF ACTIVATED HUMAN LEUKOCYTES

活化人类白细胞的临床试验

• 批准号: 3614789
• 负责人: JAMES H DOROSHOW
• 金额: $ 74.14万
• 依托单位: CITY OF HOPE NATIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-06-30 至 1991-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3614789
• 关键词: combination cancer therapy; drug adverse effect; human subject; human therapy evaluation; leukocyte activation /transformation; longitudinal human study; neoplasm /cancer immunotherapy; terminal patient care

The Contractor shall perform clinical evaluations of treatment regimens utilizing activated leukocytes sponsored by the Division of Cancer Treatment, NCI, under an investigational new drug application (IND). Specifically, the Contractor shall: 1) determine the antitumor activity of activating agents in combination with activated leukocytes in a variety of human cancers in patients with advanced disease and minimal prior therapy; 2) define the toxicities of activating agents administered in combination with activated leukocytes to patients with advanced cancer; 3) evaluate new methods for activation of leukocytes and determine the antitumor activity of activated leukocytes generated using the new methodology.

承包商应进行治疗的临床评价 利用司赞助的活化白细胞的方案 癌症治疗，NCI，根据一项研究新药 申请（IND）。 具体而言，承包商应：1） 测定活化剂的抗肿瘤活性， 在多种人类中与活化的白细胞组合 患有晚期疾病和既往最低限度癌症的患者 治疗; 2）定义给予的活化剂的毒性 与活化的白细胞联合用于患有 晚期癌症; 3）评估激活 白细胞，并确定活化的 使用新方法产生的白细胞。